2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Anticancer Agents
Anticancer agents encompass a diverse range of therapies designed to combat cancer by targeting specific aspects of tumor growth and metastasis. These agents can include chemotherapy drugs, targeted therapies, immunotherapies, and hormone therapies. Chemotherapy drugs, such as cisplatin and paclitaxel, work by interfering with the cell division process, effectively killing rapidly dividing cancer cells. Targeted therapies, like monoclonal antibodies and small molecule inhibitors, aim to disrupt specific molecules or pathways crucial for cancer cell survival and proliferation. Immunotherapies harness the power of the immune system to recognize and eliminate cancer cells. Hormone therapies are effective against hormone-sensitive cancers by blocking hormone receptors or reducing hormone production. The development of novel anticancer agents continues to revolutionize cancer treatment, offering hope for improved outcomes and enhanced quality of life for patients.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China